Abstract:e14523 Background: Adenosine and TGF-β are two key immune suppressors in tumor microenvironment (TME) that cause broad immune suppression resulting in resistance to current CPI immunotherapies. Cancer cells, and other cell types within TME, frequently express TGFβ, which inhibits CD8 + T and Th1 cells and promotes epithelial–mesenchymal transition. We have designed a bi-specific targeting molecules blocking the two inhibitory pathways, aiming to create an immune-friendly TME. Methods: We have created a bifunctional antibody–ligand trap called ES014 that comprises an antibody targeting CD39 fused to a TGFβ receptor II ectodomain sequence. ES014 molecule could simultaneously disable CD39 to prevent extracellular ATP from degradation and neutralize autocrine/paracrine TGFβ in the vicinity of target cells. The immunological function of ES014 was studied in series of in vitro immuno-assays. The in vivo efficacy of ES014 was investigated in human PBMC engrafted models. The effects of ES014 on immune cells were also analyzed using malignant pleural effusions (MPE) collected from lung cancer patients. The pharmacokinetics (PK), pharmacodynamics (PD) and safety profile were assessed in cynomolgus monkeys after intravenous administration of ES014. Results: The bispecific antibody, ES014 exhibited synergistic effects in T cell activation and suppression of Treg differentiation. ES014 activates dendritic cells, macrophages and natural killer cells by maintaining extracellular ATP level and neutralizing the immune-suppressive effects of TGFβ. Interestingly, ES014 demonstrated a unique mechanism by protecting effector T cells from activation induced cell death (AICD), which was not observed with TGFβ receptor or anti-CD39 antibody alone, or the combination of the two. The ES014 molecule is effective in inhibiting tumor progression in a PD-1 antibody-unresponsive in vivo model. Treatment of ES014 in malignant pleural effusions (MPE) collected from lung cancer patients led to the switch of M2 to M1 macrophage as indicated by increased CD86 expression and decreased CD163 expression on CD11b+ cells. Importantly, more CD8+ T cells were maintained with ES014 treatment in MPE as compared to control, resulting in significant reduction of cancer number. ES014 was well tolerated in cynomolgus monkeys, and a phase I clinical study is ongoing to investigate the safety, tolerability, PK, PD and preliminary clinical activity of ES014 in patients with advanced solid tumors. Conclusions: ES014 is a first-in-class molecule that simultaneously targeting CD39 and TGFβ. ES014 counteracts TGFβ-mediated differentiation of Tregs and adenosine-induced immune tolerance, and protected effector T cells from AICD. Treatment of ES014 resulted in significant anti-tumor effects in ex vivo and in vivo efficacy models. A single agent activity of ES014 is therefore expected in clinical trials.

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy

Abstract 5821: DXC008, a novel STEAP1 antibody-tubulysin analog conjugate with a function linker, demonstrates a potential to broaden therapeutic opportunities for prostate tumors

Abstract 61: A novel immunotherapy for metastatic prostate cancer: A monoclonal antibody that can bind both STEAP1 and STEAP2

Abstract 2618: BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models

The Antitumor Activity Of Tcr-Mimic Antibody-Drug Conjugates (Tcrm-Adcs) Targeting The Intracellular Wilms Tumor 1 (Wt1) Oncoprotein

Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions

Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells

MHC Class I-Restricted TCR-Transgenic CD4+ T Cells Against STEAP1 Mediate Local Tumor Control of Ewing Sarcoma In Vivo

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy

A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL

Broad reactivity and enhanced potency of recombinant anti-EGFR × anti-CD3 bispecific antibody-armed activated T cells against solid tumours

Preclinical characterization of a novel anti-CD39/TGFβ-trap bispecific antibody that aims to modulate tumor microenvironment.

Tumor-targeting Anti-Egfr X Anti-Pd1 Bispecific Antibody Inhibits EGFR-overexpressing Tumor Growth by Combining EGFR Blockade and Immune Activation with Direct Tumor Cell Killing

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody

In vitro and in vivo antitumor effect of a trivalent bispecific antibody targeting ErbB2 and CD16.

Abstract 2616: BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts

Abstract LB216: Discovery of BCG033, a novel anti-PTK7 x TROP2 bispecific antibody-drug conjugate with promising efficacy against triple-negative breast cancer

Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody

A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy

A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy